Hyderabad, Dec. 13 -- Novo Nordisk, a global healthcare company, on Friday announced the launch of its once-weekly diabetes drug Ozempic(R) (injectable semaglutide) in India, marking a significant addition to the country's treatment options for type 2 diabetes.
The therapy, a GLP-1 receptor agonist, is approved as an adjunct to diet and exercise for adults with uncontrolled type 2 diabetes mellitus (T2DM).
The introduction of Ozempic(R) comes at a critical time for India, which, according to WHO's 2023-24 estimates, has 101 million people living with diabetes-about 11.4% of the population-along with 136 million individuals with prediabetes and 254 million with generalised obesity, the Denmark based healthcare company said in a release her...